Nascent Biotech, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NBIO research report →
Price Chart
About the company
Nascent Biotech, Inc. , a clinical-stage biopharmaceutical firm, is committed to creating monoclonal antibody-based treatments for various forms of cancer. A primary focus is Pritumumab, a therapeutic currently in development to address aggressive brain malignancies such as glioblastoma and malignant astrocytoma.
- CEO
- Sean Carrick
- IPO
- 2009
- Employees
- 2
- HQ
- North Palm Beach, FL, US
Get TickerSpark's AI analysis on NBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $51.66K
- P/E
- -0.02
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.18
- EV/EBITDA
- -0.38
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 268.93%
- ROIC
- 1662.02%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-320,000+0.0%
- Op Income
- $-2,230,000
- Net Income
- $-2,088,000+25.5%
- EPS
- $-0.01+43.2%
- OCF Growth
- +33.6%
- FCF Growth
- +33.6%
- 52W High
- $0.08
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.63
- RSI (14)
- 54
- Avg Volume
- 10.31K
No earnings-call transcripts are available for NBIO yet.
- Free Float
- 57.7%
- Shares Outstanding
- 172.22M
- Float Shares
- 99.45M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cubic Asset Management, LLC | 105.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 24 | Karas Douglas John | other | 50,000 |
| Jun 30, 24 | HOLDEN LOWELL THOMAS | other | 96,000 |
| Jun 30, 24 | Carrick Sean | other | 192,000 |
| Mar 31, 24 | HOLDEN LOWELL THOMAS | other | 112,500 |
| Mar 31, 24 | Carrick Sean | other | 225,000 |
| Mar 31, 24 | Karas Douglas John | other | 27,100 |
| Dec 29, 23 | Carrick Sean | other | 239,300 |
| Dec 29, 23 | HOLDEN LOWELL THOMAS | other | 119,650 |
| Dec 29, 23 | Karas Douglas John | other | 28,935 |
| Sep 29, 23 | Karas Douglas John | other | 39,750 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NBIO coverage
Recent articles, reports, and earnings notes.
No research on NBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NBIO report →Nascent Biotech (OTCMKTS:NBIO) Stock Price Crosses Above 50 Day Moving Average – Time to Sell?
defenseworld.net · Aug 14
Nascent Biotech Presents at the July Emerging Growth Conference
accesswire.com · Jul 30
Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
accesswire.com · Apr 16
Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System
accesswire.com · Mar 19
Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates
accesswire.com · Feb 6
Nascent Biotech Receives an Analyst Opinion Suggesting that of the Company is Significantly Under Valued
accesswire.com · Jan 9
Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk
accesswire.com · Dec 19
Nascent Biotech Granted Japanese Patent for Crossing Blood-Brain Barrier
accesswire.com · Nov 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.